PharmAbcine Inc
208340
Company Profile
Business description
PharmAbcine Inc is a clinical stage biotech company that develops fully human therapeutic monoclonal antibody (mAb) using innovative discovery technology and excellent human resources for the treatment of human diseases, such as cancer and inflammatory diseases.
Contact
70, 2, 2nd Floor, KT Daedeok 2 Research Center
Jeonmin-dong
Yuseong-dong
Daejeon Metropolitan City1689
KORT: +82 428632017
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
40
Stocks News & Analysis
stocks
Are declining Chinese births a red flag for A2 Milk?
Demographic challenges in A2’s largest market lead to sell-off.
stocks
Is this ASX share a value trap or bargain?
Cost-cutting the priority as underlying asset values falling on deaf ears.
stocks
Goldman Sachs Earnings: Valuations remain stretched
We raise our fair value estimate for Goldman Sachs stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,108.60 | 16.20 | 0.18% |
| CAC 40 | 8,079.17 | 16.59 | 0.21% |
| DAX 40 | 24,559.86 | 143.26 | -0.58% |
| Dow JONES (US) | 48,747.01 | 258.42 | 0.53% |
| FTSE 100 | 10,151.04 | 24.26 | 0.24% |
| HKSE | 26,585.06 | 97.55 | 0.37% |
| NASDAQ | 23,090.65 | 136.33 | 0.59% |
| Nikkei 225 | 52,774.64 | 216.46 | -0.41% |
| NZX 50 Index | 13,417.17 | 156.76 | -1.15% |
| S&P 500 | 6,840.56 | 43.70 | 0.64% |
| S&P/ASX 200 | 8,782.90 | 14.00 | 0.16% |
| SSE Composite Index | 4,116.94 | 3.29 | 0.08% |